JP2017527602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527602A5 JP2017527602A5 JP2017515074A JP2017515074A JP2017527602A5 JP 2017527602 A5 JP2017527602 A5 JP 2017527602A5 JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017527602 A5 JP2017527602 A5 JP 2017527602A5
- Authority
- JP
- Japan
- Prior art keywords
- piperidine
- piperidin
- carboxylic acid
- pyridin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020035272A JP6908747B2 (ja) | 2014-09-19 | 2020-03-02 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052537P | 2014-09-19 | 2014-09-19 | |
| US62/052,537 | 2014-09-19 | ||
| PCT/IB2015/057219 WO2016042536A1 (en) | 2014-09-19 | 2015-09-18 | Novel soluble guanylate cyclase activators and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035272A Division JP6908747B2 (ja) | 2014-09-19 | 2020-03-02 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527602A JP2017527602A (ja) | 2017-09-21 |
| JP2017527602A5 true JP2017527602A5 (enExample) | 2018-10-25 |
| JP6678656B2 JP6678656B2 (ja) | 2020-04-08 |
Family
ID=54238488
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515074A Active JP6678656B2 (ja) | 2014-09-19 | 2015-09-18 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
| JP2020035272A Active JP6908747B2 (ja) | 2014-09-19 | 2020-03-02 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
| JP2021109106A Pending JP2021155450A (ja) | 2014-09-19 | 2021-06-30 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035272A Active JP6908747B2 (ja) | 2014-09-19 | 2020-03-02 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
| JP2021109106A Pending JP2021155450A (ja) | 2014-09-19 | 2021-06-30 | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9938260B2 (enExample) |
| EP (1) | EP3194384A1 (enExample) |
| JP (3) | JP6678656B2 (enExample) |
| KR (1) | KR20170054508A (enExample) |
| CN (1) | CN106687456B (enExample) |
| AU (1) | AU2015319724B2 (enExample) |
| BR (1) | BR112017005660A2 (enExample) |
| CA (1) | CA2961745A1 (enExample) |
| CL (1) | CL2017000640A1 (enExample) |
| CO (1) | CO2017002506A2 (enExample) |
| CR (1) | CR20170102A (enExample) |
| DO (1) | DOP2017000073A (enExample) |
| EA (1) | EA033697B1 (enExample) |
| IL (1) | IL251094A0 (enExample) |
| MA (1) | MA40583A (enExample) |
| MX (1) | MX2017003621A (enExample) |
| PE (1) | PE20170937A1 (enExample) |
| PH (1) | PH12017500481A1 (enExample) |
| SG (1) | SG11201701915TA (enExample) |
| WO (1) | WO2016042536A1 (enExample) |
| ZA (1) | ZA201701835B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6479029B2 (ja) | 2014-02-06 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| CA2961745A1 (en) * | 2014-09-19 | 2016-03-24 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
| CR20170100A (es) | 2014-09-19 | 2017-04-24 | Bayer Pharma Aktiengesellchaft | Indazoles sustituidos con bencilo como inhibidores bub1 |
| EP3525778A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| EP3787610A1 (en) | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| CN112384213A (zh) | 2018-05-15 | 2021-02-19 | 拜耳公司 | 用于治疗与神经纤维敏化有关的疾病的1,3-噻唑-2-基取代的苯甲酰胺 |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602143A (en) | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
| MX2009004856A (es) | 2006-11-09 | 2009-06-05 | Alcon Res Ltd | Matriz polimerica insoluble en agua para suministro de farmaco. |
| AR069517A1 (es) | 2007-12-03 | 2010-01-27 | Smithkline Beecham Corp | Compuesto del acido fenil metiloxifenil piridinil carboxilico substituido, composiciones farmaceuticas que lo comprenden y su uso para la prepara-cion de un medicamento util para el tratamiento de una enfermedad mediada por la actividad de la enzima sgc |
| WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| WO2010099054A2 (en) * | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102009012314A1 (de) * | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| JP5636296B2 (ja) | 2011-01-20 | 2014-12-03 | 公益財団法人微生物化学研究会 | 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体 |
| CA2961745A1 (en) * | 2014-09-19 | 2016-03-24 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
-
2015
- 2015-09-18 CA CA2961745A patent/CA2961745A1/en not_active Abandoned
- 2015-09-18 SG SG11201701915TA patent/SG11201701915TA/en unknown
- 2015-09-18 PE PE2017000478A patent/PE20170937A1/es unknown
- 2015-09-18 KR KR1020177010181A patent/KR20170054508A/ko not_active Ceased
- 2015-09-18 WO PCT/IB2015/057219 patent/WO2016042536A1/en not_active Ceased
- 2015-09-18 US US15/509,895 patent/US9938260B2/en active Active
- 2015-09-18 AU AU2015319724A patent/AU2015319724B2/en active Active
- 2015-09-18 MA MA040583A patent/MA40583A/fr unknown
- 2015-09-18 CR CR20170102A patent/CR20170102A/es unknown
- 2015-09-18 JP JP2017515074A patent/JP6678656B2/ja active Active
- 2015-09-18 MX MX2017003621A patent/MX2017003621A/es unknown
- 2015-09-18 CN CN201580050717.XA patent/CN106687456B/zh active Active
- 2015-09-18 BR BR112017005660A patent/BR112017005660A2/pt not_active Application Discontinuation
- 2015-09-18 EP EP15772026.9A patent/EP3194384A1/en not_active Withdrawn
- 2015-09-18 EA EA201790655A patent/EA033697B1/ru not_active IP Right Cessation
-
2017
- 2017-03-12 IL IL251094A patent/IL251094A0/en unknown
- 2017-03-14 ZA ZA2017/01835A patent/ZA201701835B/en unknown
- 2017-03-14 PH PH12017500481A patent/PH12017500481A1/en unknown
- 2017-03-16 DO DO2017000073A patent/DOP2017000073A/es unknown
- 2017-03-16 CL CL2017000640A patent/CL2017000640A1/es unknown
- 2017-03-16 CO CONC2017/0002506A patent/CO2017002506A2/es unknown
-
2018
- 2018-03-05 US US15/911,797 patent/US10472350B2/en active Active
-
2020
- 2020-03-02 JP JP2020035272A patent/JP6908747B2/ja active Active
-
2021
- 2021-06-30 JP JP2021109106A patent/JP2021155450A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527602A5 (enExample) | ||
| JP2016525076A5 (enExample) | ||
| MX2025010774A (es) | Formas en estado solido | |
| JP2019528307A5 (enExample) | ||
| JP2019505594A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| JP2017502940A5 (enExample) | ||
| JP2003521537A5 (enExample) | ||
| JP2016520131A5 (enExample) | ||
| JP2019535672A5 (enExample) | ||
| JP2013510125A5 (enExample) | ||
| JP2017528487A5 (enExample) | ||
| JP2016538313A5 (enExample) | ||
| JP2016514719A5 (enExample) | ||
| JP2017504611A5 (enExample) | ||
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| NZ592297A (en) | 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents | |
| JP2015508749A5 (enExample) | ||
| JP2013540823A5 (enExample) | ||
| JP2009515814A5 (enExample) | ||
| JP2015514806A5 (enExample) | ||
| JP2016514718A5 (enExample) | ||
| FI3555076T3 (fi) | Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja |